Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Allergic Subjects (MEDI42121085)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
MedImmune LLC
ClinicalTrials.gov Identifier:
NCT01544348
First received: January 31, 2012
Last updated: December 16, 2013
Last verified: December 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2013
  Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)